 In 2011 PF-02341066 (now named crizotinib) was approved by US FDA for some non-small cell lung cancers.In 2012 XL184/cabozantinib gained FDA approval to treat medullary thyroid cancer, and in 2016 it gained FDA and EU approval to treat kidney cancer.Tepotinib, (MSC 2156119J), has reported phase II clinical trial results on lung cancer.